<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599596</url>
  </required_header>
  <id_info>
    <org_study_id>UCHIbadan</org_study_id>
    <nct_id>NCT03599596</nct_id>
  </id_info>
  <brief_title>Monthly Versus Two Doses of Ante-Natal Intermittent Preventive Treatment With Sulphadoxine-Pyrimethamine</brief_title>
  <official_title>Monthly Versus Two Doses of Ante-Natal Intermittent Preventive Treatment With Sulphadoxine-Pyrimethamine in University College Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Hospital, Ibadan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College Hospital, Ibadan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled prospective comparative study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to be a randomized controlled comparative study conducted to compare
      the effect of monthly versus two doses of ante-natal intermittent preventive treatment with
      sulphadoxine-pyrimethamine
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of malaria parasitemia among pregnant women with monthly doses of sulphadoxine-pyrimethamine as compared to pregnant women with 2 doses of Intermittent Preventive Treatment of Malaria during Pregnancy with Sulphadoxine-Pyrimethamine (IPTp-SP).</measure>
    <time_frame>4 Months</time_frame>
    <description>Number of participants with high level of malaria parasitemia in monthly doses of sulphadoxine-pyrimethamine group will be compared with the number of participants in 2 doses of IPTp-SP group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of drug related adverse events associated with multiple doses of sulphadoxine pyrimethamine.</measure>
    <time_frame>4 Months</time_frame>
    <description>Number of participants having drug related adverse events associated with multiple doses of sulphadoxine pyrimethamine will be noted.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Two doses of sulphadoxine-pyrimethamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken twice before delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monthly doses of sulphadoxine-pyrimethamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken monthly delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulphadoxine-pyrimethamine</intervention_name>
    <description>Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly until delivery</description>
    <arm_group_label>Two doses of sulphadoxine-pyrimethamine</arm_group_label>
    <other_name>Vitadar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulphadoxine-pyrimethamine</intervention_name>
    <description>Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets twice before delivery</description>
    <arm_group_label>Monthly doses of sulphadoxine-pyrimethamine</arm_group_label>
    <other_name>Vitadar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women

          -  Gestational age between 16 and 28weeks.

          -  No history of use of sulphadoxine-pyrimethamine prior to recruitment

          -  Not on any medication for prophylaxis

        Exclusion Criteria:

          -  Anaemia

          -  HIV positive women

          -  Pre-existing medical conditions e.g diabetes mellitus, haemoglobinopathy,
             hypertension, kidney disease, heart disease, any endocrine disorder like
             hypo/hyperthyroidism, Cushing' disease, connective tissue disorders like systemic
             lupus erythematosus, antiphospholipid syndrome or any otherautoimmune disease with
             poor feto-maternal outcomes in pregnancy.

          -  History of Glucose -6-Phosphate Dehydrogenase (G6PD) deficiency in patient

          -  Allergy to sulphonamides or pyrimethamine.

          -  Non consenting patients

          -  Multiple gestations
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Sexes eligible for the study</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Agomo CO, Oyibo WA, Odukoya-Maije F. Parasitologic Assessment of Two-Dose and Monthly Intermittent Preventive Treatment of Malaria during Pregnancy with Sulphadoxine-Pyrimethamine (IPTP-SP) in Lagos, Nigeria. Malar Res Treat. 2011;2011:932895. doi: 10.4061/2011/932895. Epub 2011 Oct 26.</citation>
    <PMID>22312575</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 23, 2018</last_update_submitted>
  <last_update_submitted_qc>July 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College Hospital, Ibadan</investigator_affiliation>
    <investigator_full_name>Olaolu Olayinka ONI</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

